NEW YORK, March 6, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Cerner Corporation
(NASDAQ: CENR), Hologic Inc. (NASDAQ: HOLX), Covance Inc. (NYSE:
CVD), and Synta Pharmaceuticals Corp. (NASDAQ: SNTA). Private
wealth members receive these notes ahead of publication. To reserve
complementary membership, limited openings are available at:
http://www.AnalystsReview.com/register
--
Salix Pharmaceuticals Ltd. Analyst
Notes
On February 25, 2014, Salix
Pharmaceuticals Ltd. (Salix) announced that a New York State Supreme Court jury has issued a
verdict in its favor in a lawsuit filed against the Company by Napo
Pharmaceuticals relating to Fulyzaq™ (crofelemer). According to
Salix, the jury found that Salix was in compliance with its
contractual obligations in commercializing Fulyzaq (crofelemer) in
the U.S., and thus there was no breach in the license agreement
between the parties. Carolyn Logan,
Salix President and CEO, commented, "We are pleased with the
verdict and appreciate the thoughtfulness with which the jury
approached this case. Salix takes its contractual obligations to
its partners very seriously. We continue to believe in the future
of Fulyzaq (crofelemer) and look forward to continuing our
commercialization efforts." The full analyst notes on Salix
Pharmaceuticals Ltd. Are available to download free of charge
at:
http://www.AnalystsReview.com/03062014/SLXP/report.pdf
--
Cerner Corporation Analyst Notes
On February 26, 2014, Cerner
Corporation's (Cerner) stock increased 0.03%, ending the day at
$62.18. Over the previous three
trading sessions, shares of Cerner increased 0.16% compared to the
Nasdaq Composite which rose 0.67% during the same period. The full
analyst notes on Cerner Corporation are available to download free
of charge at:
http://www.AnalystsReview.com/03062014/CERN/report.pdf
--
Hologic Inc. Analyst Notes
On February 26, 2014, Hologic
Inc.'s (Hologic) stock increased 0.46%, ending the day at
$21.71. Over the previous three
trading sessions, shares of Hologic declined 0.16% compared to the
Nasdaq Composite which increased 0.67% during the same period. The
full analyst notes on Hologic Inc. are available to download free
of charge at:
http://www.AnalystsReview.com/03062014/HOLX/report.pdf
--
Covance Inc. Analyst Notes
On February 26, 2014, Covance
Inc.'s (Covance) stock increased 0.52%, ending the day at
$103.42. Over the previous three
trading sessions, shares of Covance increased 0.62% compared to the
Dow Jones Industrial Average which advanced 0.59% during the same
period. The full analyst notes on Covance Inc. are available to
download free of charge at:
http://www.AnalystsReview.com/03062014/CVD/report.pdf
--
Synta Pharmaceuticals Corp. Analyst
Notes
On February 26, 2014, Synta
Pharmaceuticals Corp. (Synta) announced that it will report its Q4
2013 and full year 2013 financial results on March 11, 2014, before the market opening,
followed by a conference call and webcast at 10:00 a.m. ET to discuss these results and
provide clinical updates. Synta stated that the live webcast can be
accessed via the Investor Relations section of its website, where
it will be archived. The full analyst notes on Synta
Pharmaceuticals Corp. are available to download free of charge
at:
http://www.AnalystsReview.com/03062014/SNTA/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Analysts Review